Hint mode is switched on Switch off
For swift navigation between sections

Organization: Taizhou Huaxin Pharmaceutical Investment
LEI 300300FR0GTXUWOLIP71

Organization name
Taizhou Huaxin Pharmaceutical Investment Co.,Ltd.
Country name
China
Country of registration
China
Industry
Wholesale Trade
Bond debt
1,135 mln USD

explore the most comprehensive database

800 000

bonds globally

Over 400

pricing sources

80 000

stocks

9 000

ETF

track your portfolio in the most efficient way
Bond Search
Watchlist
Excel ADD-IN
Get access
×

— Are you looking for the complete & verified bond data?

— We have everything you need:

full data on over 700 000 bonds, stocks & ETFs; powerful bond screener; over 350 pricing sources among stock exchanges & OTC market; ratings & financial reports; user-friendly interface; available anywhere via Website, Excel Add-in and Mobile app.

Register
×

Why

You will have detailed descriptive & pricing data for 650K bonds, 76K stocks, 8K ETFs
Get full access to the platform from any device & via Cbonds app
Enhance your portfolio management with Cbonds Excel Add-in
Build yield maps, make chart comparison within a click
Don't wait any longer — start using Cbonds today! Register

Latest data on

Quotes

Request sent
Access denied
Send request
Quotes provided by information providers are indicative in nature

Profile

Taizhou Huaxin Pharmaceutical Investment Co., Ltd. offer pharmaceutical drug wholesale and distribution. It also offers land development; and equipment and building leasing services.

Awards

News

20/10/2023 Fitch Ratings affirms Taizhou Huaxin Pharmaceutical Investment at "BB" (LT Int. Scale (foreign curr.) credit rating); outlook stable
20/10/2023 Fitch Ratings affirms Taizhou Huaxin Pharmaceutical Investment at "BB" (LT Int. Scale (local curr.) credit rating); outlook stable
19/10/2023 Fitch Affirms Taizhou Huaxin at 'BB'; Outlook Stable (Rating action commentary)
13/12/2022 Fitch Ratings affirms Taizhou Huaxin Pharmaceutical Investment at "BB" (LT Int. Scale (foreign curr.) credit rating); outlook stable
13/12/2022 Fitch Ratings affirms Taizhou Huaxin Pharmaceutical Investment at "BB" (LT Int. Scale (local curr.) credit rating); outlook stable
All organization news

Documentation

IFRS/US GAAP reports

2020
II q eng
Authorization required
You need to request access

Stocks

Latest issues

Show all

Bond debt by currency

Show more Hide

Codes

  • LEI
    300300FR0GTXUWOLIP71
  • SIC
    5122 WHOLESALE-DRUGS, PROPRIETARIES & DRUGGISTS' SUNDRIES

Credit and ESG Ratings

Macroeconomic Indicators - Taizhou Huaxin Pharmaceutical Investment

Registration is required to get access.